StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis 4. Cardiovascular, Renal & Metabolic by Quarter

4. Cardiovascular, Renal & Metabolic ($M)

QuarterlyAnnual

Novartis 4. Cardiovascular, Renal & Metabolic: $1,702M in Q3 2026, down 22.1% from a year earlier.

Latest, Q3 2026
1,702
Period ended Sep 30, 2026
Change on a year earlier
-22.1%
2,185 in Q3 2025
History
16 quarters
Since Q4 2022
Sources
12
Documents cited below

Where the Q3 2026 figure comes from

“|| Total cardiovascular, renal and metabolic | 1 702 | 2 185 | – 22 | – 22”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K (Net sales by therapeutic area) & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEnded4. Cardiovascular, Renal & Metabolic ($M)Year on yearSource
Q3 2026Sep 30, 20261,702-22.1%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 20261,688-36.4%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 20261,773-29.6%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 20251,601-33.4%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 20252,185+5.9%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 20252,655+27.6%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 20252,518+24.0%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 20242,403+36.7%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 20242,063+31.0%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 20242,080+30.5%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 20242,030+38.8%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 20231,758+31.9%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 20231,575–Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 20231,594–Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 20231,463–Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 20221,333–Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up 4. Cardiovascular, Renal & Metabolic

Cite this data

StockData. (2026). Novartis 4. Cardiovascular, Renal & Metabolic ($M), quarterly Q4 2022–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/ta-crm

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.